Pacira Net Income from 2010 to 2024

PCRX Stock  USD 30.05  0.36  1.21%   
Pacira Pharmaceuticals Net Income yearly trend continues to be fairly stable with very little volatility. Net Income is likely to outpace its year average in 2024. During the period from 2010 to 2024, Pacira Pharmaceuticals Net Income regression line of annual values had significance of  0 and arithmetic mean of (1,057,817). View All Fundamentals
 
Net Income  
First Reported
2008-12-31
Previous Quarter
24.9 M
Current Value
M
Quarterly Volatility
20.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pacira Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacira main balance sheet or income statement drivers, such as Depreciation And Amortization of 79.4 M, Interest Expense of 16.1 M or Selling General Administrative of 63.1 M, as well as many exotic indicators such as Price To Sales Ratio of 2.19, Dividend Yield of 0.0 or PTB Ratio of 1.7. Pacira financial statements analysis is a perfect complement when working with Pacira Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Pacira Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Pacira Pharmaceuticals Technical models . Check out the analysis of Pacira Pharmaceuticals Correlation against competitors.
For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.

Latest Pacira Pharmaceuticals' Net Income Growth Pattern

Below is the plot of the Net Income of Pacira Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Pacira Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Pacira Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Pacira Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacira Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 41.95 M10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Pacira Net Income Regression Statistics

Arithmetic Mean(1,057,817)
Coefficient Of Variation(5,109)
Mean Deviation39,761,262
Median(11,016,000)
Standard Deviation54,045,496
Sample Variance2920.9T
Range209.4M
R-Value0.70
Mean Square Error1606.3T
R-Squared0.49
Significance0
Slope8,453,779
Total Sum of Squares40892.8T

Pacira Net Income History

202444.1 M
202342 M
202215.9 M
202142 M
2020145.5 M
2019-11 M
2018-471 K

Other Fundumenentals of Pacira Pharmaceuticals

Pacira Pharmaceuticals Net Income component correlations

About Pacira Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Pacira Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Pacira Pharmaceuticals investors use historical funamental indicators, such as Pacira Pharmaceuticals's Net Income, to determine how well the company is positioned to perform in the future. Although Pacira Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Pacira Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pacira Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pacira Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pacira Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income42 M44.1 M
Net Income From Continuing OpsM7.3 M
Net Income Applicable To Common Shares18.3 M19.2 M
Net Income Per Share 0.91  0.95 
Net Income Per E B T 0.68  1.17 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Pacira Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacira Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacira Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacira Pharmaceuticals Stock:
Check out the analysis of Pacira Pharmaceuticals Correlation against competitors.
For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Pacira Stock analysis

When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.291
Earnings Share
1.51
Revenue Per Share
14.706
Quarterly Revenue Growth
0.042
Return On Assets
0.0376
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.